Acadia Pharmaceuticals (NASDAQ: ACAD) reported an insider stock sale by Chief Executive Officer Owen Adams Catherine on March 25, 2026. Catherine sold 11,641 shares at $21.47 per share, resulting in a transaction valued at approximately $249,932.
The disposition came after the conversion of 23,509 Restricted Stock Units (RSUs) on March 24, 2026. Those RSUs converted into common stock at a price of $0.
Following the sale, Owen Adams Catherine directly holds 14,803 shares of Acadia Pharmaceuticals.
Market performance for Acadia has been uneven in recent periods. The stock is trading down about 20% year-to-date while showing a roughly 25% gain over the trailing 12 months. Valuation metrics provided in company data show Acadia currently trades at a price-to-earnings ratio of 9.4. According to InvestingPro analysis, which includes Fair Value estimates and Pro Research Reports, the stock appears undervalued.
Investors have also been watching Acadia's company announcements and regulatory developments. The company released its financial results recently, which have drawn attention from the market. Separately, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on Acadia's application for trofinetide, a therapy for Rett syndrome, citing concerns about the treatment's effectiveness and aspects of the study design.
On the corporate governance front, Acadia announced the appointment of Jonathan M. Poole to its board of directors and to the audit committee; the company board approved the appointment.
Analyst activity has reflected the mix of price movement and company news. BofA Securities was noted in recent commentary for upgrading Acadia Pharmaceuticals to a Buy rating from Neutral, stating that the recent share price pullback did not reflect fundamental problems. The firm’s price target is cited at $29. However, BofA is also reported to have lowered a prior price target from $31 to $29 while maintaining a Neutral rating, attributing that change to a pipeline review and the EU setback.
These developments - insider selling after RSU conversion, regulatory scrutiny in the EU, recent financial disclosure, a board appointment, and divergent analyst notes - provide a snapshot of the company’s recent activity and the range of factors market participants are weighing.